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Type 2 diabetes (T2D) and associated elements of cardiometabolic diseases (CMD) are multifactorial disorders resulting from the effects of many genes interacting with environmental factors. The gut microbiota sits at the interface between the environment and the host organism and contributes to the metabolism of nutrients into digestible molecules and the maturation of immune processes. The involvement of the gut microbiota in T2D and obesity has been mainly addressed through metagenomic sequencing, which identified changes in microbiome architecture [1] [2] [3] and gene richness 4 . This concept of microbiome-host crosstalk is also supported by instances of associations between CMD and microbialmammalian co-metabolites (eg. hippurate, methylamines, short chain fatty acids) 5 that metabolomic technologies can detect and quantify in biofluids. Metabolomics is able to quantitatively and qualitatively analyze a broad range of small molecules, which are molecular endpoints of the combined expression of the host genome and the microbiome 6 .
Metabolic endophenotypes generated by metabolomic-based phenotyping and metabotyping 7 can be used as biomarkers underlying disease etiology 8, 9 and help understand disease pathogenesis and develop relevant therapeutic solutions.
Considering the importance of microbiome-host metabolic axis in chronic diseases 10, 11 , we set out to investigate interactions of risk factors for T2D and obesity and gut microbial metabolites. We used a semi-targeted gas chromatography coupled to mass spectrometry (GC-MS) approach to profile plasma metabolites and test their association with T2D and obesity. Simultaneous analysis of 101 metabolites identified a metabotype of 18 metabolites associated with the diseases, including products of gut microbial metabolism (eg. 4-cresol) .
Chronic administration of 4-cresol in preclinical models of spontaneous or experimentallyinduced insulin resistance resulted in significantly improved glucose homeostasis, enhanced glucose-stimulated insulin secretion in vivo, reduced adiposity and increased pancreas weight.
Further physiological, histological and molecular analyses in 4-cresol treated animals indicated reduction in inflammation and enhancement of both cell proliferation and vascularisation in the pancreas, which may be mediated by downregulated expression of the kinase DYRK1A by 4-cresol 12 and upregulated expression of SIRT1. Our findings illustrate the contribution of gut microbial metabolites in chronic diseases through the identification of 4-cresol as a regulator of T2D endophenotypes with potential therapeutic applications.
RESULTS

Clinical and biochemical data analysis
The study population consisted of 138 phenotypically well characterized patients with a mean age of 54.96 (± 1.01) years, a mean body weight of 77.84 kg (± 1.23) and a mean BMI of 28 .04 kg/m 2 (± 0.42). T2D identification was based on clinical documentation in the patients' medical charts. Among these, 77 were classified as high CMD risk patients with elevated BMI (>30kg/m 2 ) (24%), low plasma HDL cholesterol (<40mg/dL) (50%) and fasting hyperglycemia (>125mg/dL) (10%). These were classified as cases (77), whilst the remaining 61 subjects were classified as control. There were no significant gender differences for any of these phenotypes.
Metabolic profiling identifies a metabotype associated with T2D and obesity
To identify quantitative variations in circulating metabolites that can account for clinical features and biochemical measures in the population, serum samples from cases and controls were processed by GC-MS for metabolic profiling. A total of 101 metabolites were targeted in the GC-MS spectra and used for association analysis with clinical phenotypes in the study population (Supplementary Table 1 ). The targeted metabolites included 36 amino acids, 32 organic acids, 20 sugars, and other molecular compounds (eg. nucleobases).
We carried out focused analyses of association between metabolites and T2D and obesity.
We first built an orthogonal partial least squares discriminant analysis (O-PLS-DA) using GC-MS data to stratify the population based on T2D and obesity (Figure 1A) . The goodnessof-prediction (Q 2 Yhat statistic = 0.36) of the model assessed by 7-fold cross-validation was deemed significant by permutation testing (p = 10 -5 based on 100,000 iterations) ( Figure 1B) .
Model coefficients supporting this discrimination were validated against logistic regressions adjusted for age and gender and highlighted a signature made of 14 metabolites (2aminoadipic acid, arabinose, 2-deoxytetronic acid, gluconic acid, glucose, 2-hydroxybutyric Figure 1. Metabolic profiling identifies microbial metabolites associated with type 2 diabetes. Data from serum metabolites acquired by gas chromatography mass spectrometry (GC-MS) and clinical variables in the cohort were used to derive OPLS-DA scores plot (A). Validation of goodness-of-fit (R 2 ) and goodness-of-prediction (Q 2 ) parameters were obtained by permutation testing (n=100 random permutations) (B). Variable contributions (r) to the O-PLS-DA model, confirmed by logistic regression are shown in green and red for negative and positive correlations with the disease, respectively. Statistics were corrected for multiple comparisons and adjusted for age and gender effects.
acid, 3-hydroxyisobutyric acid, 2-and 3-hydroxyisovaleric acid, indolelactic acid, isocitric acid, mannose, ribulose, valine) significantly positively correlated with T2D and obesity and 4 metabolites (1,5-anhydro-D-sorbitol, 4-cresol, glyceric acid and 5-oxoproline) negatively correlated with the diseases (Figure 1C ). 4-cresol was the microbial metabolite the most significantly associated with reduced disease risk.
These results demonstrate the power of systematic and simultaneous metabolomic-based profiling of a large series of metabolites to identify metabotypic endophenotypes associated with diseases, and point to the microbial metabolite 4-cresol as a novel biomarker of reduced risk of T2D and obesity.
4-cresol treatment improves glucose homeostasis and reduces body weight gain in mice
To test the biological role of microbial metabolites in vivo we prioritized experimental validation of the clinical association on 4-cresol, which suggested potential benefits for T2D and obesity. We chronically treated mice fed control diet or high fat diet (HFD) with subcutaneous infusion of a solution of 4-cresol 0.04M, corresponding to approximately 0.5mg/kg/day, for 42 days. Subcutaneous treatment was preferred over dietary supplementation or oral gavage in order to control permanent delivery of 4-cresol over a long period of time and reduce the stress induced by animal handling. This delivery method also avoided possible toxic effects of this volatile compound that are observed at much higher doses (240-2000mg/kg/day) on neurological function, liver function and respiratory epithelium 13 . As expected, mice fed HFD rapidly gained more weight than mice fed control diet and developed fasting hyperglycemia and marked glucose intolerance (Figure 2A-F) .
Glycemia after the glucose challenge, cumulative glycemia during the test and the ΔG parameter were significantly more elevated in mice fed HFD than in controls (Figure 2C-F) .
Fasting insulin and glucose-induced insulin secretion were not significantly affected by HFD ( Figure 2G ).
Figure 2. Chronic administration of 4-cresol improves glucose homeostasis, stimulates insulin secretion and reduces obesity in C57BL6/J mice.
The effects of 6-week long administration of 4-cresol in vivo in mice fed control chow or high fat diet (HFD) were tested on body weight (A), body mass index (BMI) (B), glucose homeostasis (C-F), glucosestimulated insulin secretion (G), organ weight (H-J) and liver triglycerides (K). BMI was calculated as body weight divided by the squared of anal-nasal length. AUC was calculated as the sum of plasma glucose values during the IPGTT. ΔG is the AUC over the baseline value integrated over the 120 minutes of the test. All measures are from 6 mice per group.
Data were analyzed using the unpaired Mann-Whitney test. Results are means ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001, significantly different to relevant controls.
IRI, immunoreactive insulin
Chronic infusion of mice fed control diet with 4-cresol resulted in progressive reduction in body weight when compared to mice treated with saline (Figure 2A) . This effect became significant after 4 weeks of 4-cresol treatment and remained significant until the end of the experiment. BMI was also significantly decreased after six week of 4-cresol treatment ( Figure 2B) . Glucose tolerance was improved by 4-cresol, as indicated by the significant reduction in both acute glycemic response to the glucose challenge and cumulative glycemia during the IPGTT when compared to saline-treated mice (Figure 2C,D) . 4-cresol infusion resulted in a significant increase in glucose-stimulated insulin secretion when compared to controls ( Figure 2G ).
The effect of 4-cresol on body weight, glycemic control and insulin secretion was also strongly significant in HFD-fed mice (Figure 2A-G) . In addition, 4-cresol treatment in fat fed mice induced strong reduction in fasting glycemia ( Figure 2F ) and in the ΔG parameter, which was normalized to the level of mice fed chow diet and treated with saline ( Figure 2E) , and fasting hyperinsulinemia ( Figure 2G ) when compared to HFD-fed mice infused with saline.
In vivo 4-cresol treatment alters organ weight and reduces liver triglycerides
To further characterize the effects of 4-cresol on phenotypes relevant to T2D and obesity, we measured organ and tissue weights, and analysed phenotypes frequently associated with obesity (eg. fatty liver disease) in the mouse groups. After seven weeks of HFD, mice exhibited significantly elevated adiposity, which was calculated as the ratio of the retroperitoneal fat pad weight to body weight ( Figure 2H ) and reduced heart weight ( Figure   S1 ) when compared to mice fed chow diet. Liver triglycerides levels were markedly increased by HFD but this effect was not statistically significant ( Figure 2K) .
In both diet groups, chronic administration of 4-cresol over 6 weeks resulted in significant reduction in adiposity index ( Figure 2H ) and increased pancreas weight by 48.9% ( Figure  2I ) when compared to mice treated with saline. Heart and kidney weight were not affected by 4-cresol ( Figure S1 ). Liver weight was reduced in HFD-fed mice treated with 4-cresol ( Figure 2J ). 4-cresol treatment resulted in a systematic and dramatic reduction in liver triglycerides content in both diet groups (Figure 2K) .
Collectively, these data demonstrate the beneficial effects of chronic administration of 4cresol in vivo in mice on obesity, thus validating our results from metabolomic profiling in patients, and extend the characterization of its beneficial effects on improved glucose tolerance and reduced triglycerides in the liver.
4-cresol derivative 4-methylcatechol mimics the biological effects of 4-cresol
We then investigated whether these physiological effects are specific to 4-cresol or can be replicated with other products of microbial metabolism structurally related to 4-cresol. We 
Chronic 4-cresol treatment ameliorates histological features in adipose tissue and liver
To characterize the effects of 4-cresol on adiposity and lipid metabolism at the organ level, we carried out histological analyses of adipose tissue and liver in the four mouse groups (Figure 3A-D) . HFD feeding induced a strongly significant increase (84.8%) in adipocyte size (56.27 ± 0.47 in CHD fed mice and 104.00 ± 1,41 in HFD fed mice) ( Figure 3A,B) , which is consistent with increased adiposity in response to fat feeding. In CHD fed mice 4cresol induced a slight reduction in adipocyte diameter when compared to saline-treated mice (53.97 ± 0.39, P=0.006). Remarkably, 4-cresol administration in HFD fed mice led to a strongly significant reduction of adipocyte size (66.22 ± 0.70, P<0.0001) to a level close to that of saline treated CHD-fed controls (Figure 3A,B) .
Occurrence of liver structural lesions resembling non alcoholic fatty liver disease (NAFLD)
is a phenotypic hallmark consistently observed in obese mice fed HFD in our experimental conditions 15 . To investigate the effect of 4-cresol on these defects and test the histological relevance of reduced liver triglycerides observed in mice treated by 4-cresol ( Figure 2K ), we carried out liver histology in the four mouse groups. HFD feeding induced a strongly significant 4.27-fold increase in liver fat content determined by Oil-Red-O staining of liver sections (Figure 3C,D) . In response to 4-cresol infusion, liver fat content was reduced in mice fed CHD. It was also strongly reduced by 40.7% in HFD fed mice (P=0.009) to levels similar to saline-treated CHD-fed controls (Figure 3D ).
Gene expression changes induced by chronic 4-cresol treatment in adipose tissue
To investigate molecular changes potentially underlying morphological changes in adipose tissue caused by 4-cresol treatment, we analysed the expression of a selection of genes known to regulate adipocyte function in obesity ( Figure S3 ). Expressions of sirtuin 1 (Sirt1), caveolin 2 (Cav2), hormone-sensitive lipase (Hsl) and patatin-like phospholipase domain containing 2 (Pnpla2, Atgl) were significantly stimulated by 4-cresol in CHD fed mice, whereas uncoupling protein 1 (Ucp1) expression was markedly downregulated. Expression of Hsl and Pnpla2 remained significantly upregulated by 4-cresol in HFD-fed mice when compared to saline treated fat fed mice, and Ucp1 was significantly downregulated in these mice when compared to both HFD-fed mice treated with saline and CHD-fed mice treated with 4-cresol.
Chronic 4-cresol administration increases pancreatic vascularisation and islet density and promotes cell proliferation
One of our most striking observations was the massive effect of 4-cresol on increased pancreas weight in both diet groups (Figure 2I) , which we analysed further through histology of pancreas sections. To test whether islet structure was affected by 4-cresol, we focused histopathology analyses on islets in sections stained by HE. Fat feeding did not affect overall insulin positive area (58.95 ± 11.75 in CHD fed mice; 109.03 ± 24.15 in HFD fed mice, P=0.071) (Figure 4A,B) , but significantly increased islet density (Figure 4C,D) . 4-cresol administration was associated with a strong increase in both islet density and insulin positive area in mice fed CHD (185.40 ± 22.95) or HFD (171.90 ± 21.62), but the effect was statistically significant only in CHD-fed mice (Figure 4A-D) . We noted that islets in pancreas sections of cresol treated mice were predominantly located in the close vicinity of the vasculature (Figure 4G ), suggesting an effect of 4-cresol on enhanced islet neogenesis.
To investigate the possible cause of increased β-cell area and islet density induced by 4cresol, we next used Ki67 to determine pancreatic cell proliferation in the four mouse groups 
4-cresol stimulates insulin content and cell proliferation in isolated mouse islets
To confirm the functional role of 4-cresol in pancreatic islets, we incubated islets isolated from mice with a concentration of 4-cresol (10nM) corresponding to the dose administered in vivo in mice, and a higher dose (100nM). The lower dose of 4-cresol induced a strong increase in insulin release under basal condition (2.8mM glucose) (+17.3%), a marked stimulation of insulin secretion in response to glucose 16.6mM (+25.8%, p=0.06) ( Figure   6A ), and a significant increase in islet insulin content (+33.7%, p<0.05) ( Figure 6B) .
Incubation with 4-cresol at 100nM had no effect on insulin production, secretion and content.
Labeling of islets with KI67 revealed a significant effect of 4-cresol 10nM on increased islet cell proliferation (Figure 6C,D) , as illustrated in Figure 6E . 
4-cresol treatment improves glucose homeostasis and boosts insulin secretion and islet density in the Goto-Kakizaki rat
The impact of 4-cresol on enhanced insulin secretion and stimulated islet cell proliferation in vivo in a model of diet-induced insulin resistance and in vitro in isolated islets prompted us to test 4-cresol in a preclinical model of diabetes characterized by spontaneously-occurring reduction of β-cell mass. We used the Goto-Kakizaki (GK) rat, which exhibits glucose intolerance and deteriorated islet structure as a result of repeated breeding outbred Wistar rats over many generations using glucose intolerance for selecting breeders 16 . Chronic administration of 4-cresol had no effect on body weight and BMI in this model of non obese diabetes (Figure S4) . In contrast, adiposity index was significantly reduced, even though the GK is not a model of obesity, and pancreas weight nearly doubled (+94.6%, P<0.01) in 4cresol treated rats (Figure 7A,B) . This effect of 4-cresol was associated with a significant reduction in fasting glycemia (Figure 7C ) and in glucose intolerance, assessed by a decrease in the glycemic response to the glucose challenge throughout the IPGTT (Figure 7D ) and the significant drop in cumulative glycemia (Figure 7E-F) . Fasting insulinemia and glucoseinduced insulin secretion during the IPGTT were significantly more elevated in GK treated with 4-cresol than in rats treated with saline ( Figure 7G) . Pancreas histology analyses showed a significant increase in insulin positive area in response to 4-cresol, which was associated with increased cell proliferation determined by Ki67 labeling (Figure 7H-J) .
These results strongly support data obtained in HFD-fed mice and demonstrate that 4-cresol administration dramatically improves diabetes phenotypes in a model characterized by spontaneously occurring insulin deficiency and deteriorated islet structure. 
4-cresol chronic treatment is associated with profound changes in pancreas gene expression
To get insights into molecular mechanisms that contribute to structural and functional changes induced by 4-cresol in the pancreas in vivo, expression of selected genes covering various aspects of pancreas biology was tested by quantitative RT-PCR in HFD-fed and control mice (Figure 8A ) and in GK rats (Figure 8B) . Expression of uncoupling protein 2 (Ucp2), interleukins (Il6, Il10) and tumor necrosis factor (Tnfa) was increased by HFD Hnf1α and Vegf were also strongly overexpressed in response to 4-cresol in these mice but differences to saline treated mice fed HFD were not statistically significant.
The stimulatory effects of 4-cresol chronic administration on the expression of Sirt1, Ins1, Hnf1α, Il10 and Vegfa were replicated in GK pancreas (Figure 8B) . Expression of genes encoding amylase, Il6 and Tnfa was strongly altered in 4-cresol treated GK rats, but differences to controls treated with saline were not statistically significant.
Due to strong similarities in the biological effects of 4-cresol and harmine, an inhibitor of the dual specificity tyrosine phosphorylation regulated kinase (DYRK1A) known to stimulate βcell proliferation 17, 18 , we tested the expression of this gene in fat fed mice and GK rats 
DISCUSSION
We report correlations between type 2 diabetes (T2D) and obesity and variations in serum concentration of a series of metabolites derived by GC-MS based metabolomics. Significant associations were found with metabolic products of gut microbial metabolism, including 4cresol, which was tested for its biological role in vivo in preclinical models of spontaneous or experimentally-induced diabetes and in vitro in β-cells. We demonstrate that 4-cresol improves glycemic control, enhances glucose-stimulated insulin secretion, reduces adiposity and liver triglycerides and stimulates pancreatic islet density, vascularisation and cell proliferation in vivo and in vitro. These effects mimic metabolic improvements induced by harmine, and may be mediated through downregulated expression of DYRK1A.
Our metabolomic approach identified systematic correlations between T2D and obesity and a metabotype 7 of 18 co-associated metabolites, which covers obvious candidates for these conditions, including for example glucose, branched chain amino acids and mannose, which was recently associated with obesity and is proposed as an accurate marker of insulin resistance 19 . Glucose-and mannose-mediated inhibition of cellular uptake of 1,5-anhydro-Dsorbitol 20 , a marker of short-term glycemic control 21 , supports the strongly significant negative correlation between serum 1,5-anhydro-D-sorbitol and T2D and obesity in our study. The metabotype significantly correlated with these diseases also includes 2hydroxybutyric acid, which is elevated in plasma of T2D patients 22 and could be a predictive marker of insulin resistance 23 , and 2-amino adipic acid which is associated with T2D risk 24 .
Stimulation of insulin secretion in vitro 24 by 2-amino adipic acid and its regulation by the dehydrogenase E1 and transketolase domain-containing 1 gene (DHTKD1), which plays critical roles in diabetes pathogenesis 25 and in mitochondrial energy production and biogenesis 26 , suggest broad ranging roles of 2-amino adipic acid in the pathogenesis of metabolic disorders.
There is growing interest in understanding the impact of structural changes in gut bacterial communities on host metabolism 1, 11 and disease pathogenesis 2, 27 . We demonstrate significant correlations between the microbial metabolite 4-cresol and T2D and obesity. 4cresol is a product of colonic fermentation of tyrosine and phenylalanine 28 , which can be also These data suggest convergent biological roles of natural products or polyphenols and the phenol derivative 4-cresol, which may share ligands and signalling mechanisms leading to improved glucose homeostasis. We showed that 4-cresol and harmine exhibit very similar effects on increased islet mass and improved glucose regulation 38 . Harmine directly targets the kinase DYRK1A 39 resulting in its inhibition and in increased human β-cell proliferation, β-cell mass and insulin content 17, 18 . Interestingly, the role of polyphenols on DYRK1a inhibition is suggested by the rescue of neurobehavioral deficits in transgenic mice overexpressing DYRK1a through treatment with green tea polyphenols 40 . Our results indicate that 4-cresol is also a DYRK1A inhibitor and support the emerging role of kinases in mediating the cellular function of microbial metabolites 41 .
In conclusion, our findings illustrate the power of systematic metabolic profiling to identify a metabotype integrating microbial metabolites that are biological endpoints of gut microbiome architecture and reflect gut microbiota function in chronic diseases. We demonstrate the 
Materials and Methods
Full details of Material s and Methods are available in Supplementary Material
Study Subjects
We used plasma samples from 138 subjects of the FGENTCARD collection 42 .
Gas chromatography coupled to mass spectrometry (GC-MS)
GC-MS analysis was performed using a GCMS-QP2010 Ultra (Shimadzu, Kyoto, Japan). By comparing mass spectral pattern of chromatographic peaks to those in the NIST library or Shimadzu Database, 101 metabolites were identified (Supplementary Table 1 ).
Animal experiments
C57BL/6J mice were from a commercial supplier (Janvier Labs, Courtaboeuf, France). Goto- 
In vitro insulin secretion in mouse isolated islets
Islets were isolated in a solution containing collagenase (Roche, Sigma Aldrich, St Quentin, France) and purified on a four layer density gradient of Histopaque 1119 (Sigma-Aldrich, France). Islets incubated with the culture medium or cresol (10nM or 100nM) (W233706, Sigma Aldrich, St Quentin, France) were either prepared to determine insulin content or incubated with 2.8 or 16.7mM glucose.
Histology of animal tissues and isolated islets
Tissue sections were stained in Hematoxylin and Eosin. Antibodies were used for immunohistochemistry detection of insulin on pancreas sections (Dako, Saint Aubin, France). 
Liver
Gene expression
Quantitative RT-PCR was performed using SYBR green assays (Eurogentec, Angers, France). Primers are listed in Supplementary Table 2 .
DYRK1A analyses
4-cresol binding to DYRK1A was assessed as previously described 43, 44 . The dissociation constant (Kd) was calculated from duplicate 12-point dose-response curve. The DYRK1A
half-maximal inhibitory curve (IC50) for 4-cresol was determined using Kinexus service (Kinexus, Vancouver, Canada).
Analytical assays
Blood glucose was measured using Accu-Check® Performa (Roche Diagnostics, Meylan, France) and plasma insulin was determined by ELISA (Mercodia, Uppsala, Sweden). Liver triglycerides were determined using a colorimetric assay (Abcam, Paris, France).
NAD/NADH was determined using a quantification kit (Sigma Aldrich, St Quentin, France).
Statistical analyses
R statistics was used to compute P-values for correlations between metabolic features and clinical data. Multivariate modelling of the signature related to diabetes and obesity was performed through Orthogonal Partial Least Squares Discriminant Analysis 45 . All p-values were corrected for multiple testing using the Benjamini-Hochberg procedure. Supplementary Table 1 . Mass spectrometry features of metabolites analysed in serum samples in the cohort of coronary artery disease patients (n=77) and controls (n=61). A typical spectrum is shown in Supplementary Figure 1 . 
Supplementary Methods
Study Subjects
A total of 138 subjects (90 males and 48 females) recruited between 2006 and 2009 for inclusion in the FGENTCARD patient collection (1) were selected on the basis of extreme levels of plasma HDL cholesterol, presence of coronary stenosis and a positive family history of the disease, defined as a sibling, parent, or second-degree relative with a coronary event. Presence of diabetes, hypertension or obesity was recorded. These subjects were originally referred to a catheterization care unit for clinical evaluation. Patients provided a written consent for the whole study including genomic analyses. The study protocol was approved by the Institutional Review Board at the Lebanese American University.
Chemicals
Purified water (TOC grade), methanol (residual PCB grade), chloroform (residual PCB grade), and pyridine dehydrated were purchased from Wako Pure Chemical Industries (Osaka, Japan).
Methoxyamine hydrochloride and 2-isopropylmalic acid were obtained from Sigma-Aldrich (Sigma-Aldrich, Tokyo, Japan).
Sample preparation
The internal standard solution (2-isopropylmalic acid, 0.1 mg/mL in purified water) and extraction solvent (methanol: water: chloroform = 2.5:1:1) were mixed at a ratio of 6:250, which was added to 50L of each plasma sample. The resulting solution was mixed using a shaker at 1,200 rpm for 30 min at 37°C. After centrifugation at 16,000 x g for 5 min at 4°C, 150L of supernatant was collected and mixed with 140L of purified water. The solution was thoroughly mixed and centrifuged at 16,000 x g for 5 min at 4°C. Finally, 180L of supernatant was collected and lyophilized. The lyophilized sample was dissolved in 80L of methoxyamine solution (20 mg/mL in pyridine) and agitated at 1,200 rpm for 30 min at 37°C. Forty micro litters of N-methyl-N-trimethylsilyltrifluoroacetamide solution (GL science, Tokyo, Japan) were added for trimethylsilyl derivatization, followed by agitation at 1,200 rpm for 30 min at 37°C. After centrifugation at 16,000 x g for 5 min at room temperature, 50 L of supernatant was transferred to a glass vial and subjected to GC-MS measurement.
Gas chromatography coupled to mass spectrometry (GC-MS)
GC-MS analysis was performed using a GCMS-QP2010 Ultra (Shimadzu, Kyoto, Japan Blood glucose and body weight were monitored weekly during the 6-week long administration of 4-cresol or saline. After three (mice) or four (rats) weeks of treatment (i.e. four weeks of HFD feeding in mice) an intraperitoneal glucose tolerance test (IPGTT) (2g/kg in mice, 1g/kg in rats) was performed in conscious animals following an overnight fast. For the IPGTT carried out in mice, blood was collected from the tail vein before glucose injection and 15, 30, 60 and 120 minutes afterwards. Additional blood samples were collected during the IPGTT in GK rats 15, 90, 180 and 240 minutes after glucose injection. Blood glucose levels were determined using an Accu-Check® Performa (Roche Diagnostics, Meylan, France). Additional blood samples were collected at baseline and 30 minutes after glucose injection in Microvette® CB 300 Lithium Heparin (Sarstedt, Marnay, France). Plasma was separated by centrifugation and stored at -80°C until insulin radioimmunoassay. Evaluation of overall glucose tolerance was obtained from the cumulative glycemia (GCum) and the ΔG, which were determined by the total increment of plasma glucose values during the IPGTT (GCum) and the cumulative glycemia during the test above baseline (ΔG).
After six weeks of metabolite treatment, animals were killed by decapitation and organs were dissected and weighed. Half of liver, fat and pancreas samples were snap frozen in liquid nitrogen and stored at -80°C for molecular studies, and the second half processed for histopathology.
All procedures were carried out under national French licence condition (Ref 00486.02) and
were authorized following review by the institutional ethics committee of the University Pierre and Marie Curie.
In vitro insulin secretion in mouse isolated islets
Eleven-weeks-old male C57Bl/6J (Janvier-Labs, Saint-Berthevin, France) were killed by cervical 
